BicycleTx Limited
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS8
PHASE 3 / 2-30
RECRUITING1
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO50%
Delay Index: of 6 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +11.0 months). See all sponsors →
Open BicycleTx Limited on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| BT7480 NCT05163041 |
P1/2 | Active, not recruiting | Advanced Solid Tumor | 200 | 2026-08 (+11 mo) |
| BT5528 NCT04180371 |
P1/2 | Active, not recruiting | Advanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer | 288 | 2026-12-31 (+48 mo) |
| BT8009 NCT04561362 |
P1/2 | Active, not recruiting | Urinary Bladder Neoplasm; Triple Negative Breast Neoplasms | 329 | 2027-01 (+43 mo) |
| Zelenectide pevedotin NCT06225596 |
P2 | Active, not recruiting | Metastatic Urothelial Cancer | 375 | 2028-03 (-33 mo) |
| Zelenectide pevedotin (BT8009) NCT06840483 |
P2 | Active, not recruiting | Breast Cancer | 66 | 2028-06-30 |
| Zelenectide pevedotin NCT06933329 |
P2 | Active, not recruiting | Non-Small Cell Lung Cancer | 73 | 2028-08-31 |
| nuzefatide pevedotin (BT5528) NCT07450859 |
P2 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC) | 39 | 2029-03 |
| Zelenectide pevedotin NCT07681674 |
P2 | Not yet recruiting | Advanced Solid Tumors | 16 | 2030-05-30 |